Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29616475 | 0.85 | KMT2A (0.54) | KMT2AEPHX2CASP3 | |
| SCHEMBL18982241 | 0.85 | KMT2A (0.49) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL19931854 | 0.85 | KMT2A (0.54) | KMT2AEPHX2CASP3 | |
| SCHEMBL4690513 | 0.84 | KMT2A (0.49) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL23014550 | 0.83 | KMT2A (0.44) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL25190907 | 0.82 | KMT2A (0.47) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL3630096 | 0.82 | KMT2A (0.48) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL3888794 | 0.82 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL26172640 | 0.82 | KMT2A (0.60) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL18411293 | 0.82 | KMT2A (0.55) | KMT2AEPHX2FABP5FABP7CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2113513-B1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20090298765-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-03 | — | — | US | disclosed |
| US-7625869-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-2113513-A2 | Metastin derivatives and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | KMT2A 1848/4885EPHX2 3564/4885FABP5 2485/4885 |
| US-20090298765-A1 | Metastin derivatives and use thereof | GNRHR, SHBG, MEN1 | KMT2A 1848/4885EPHX2 3564/4885FABP5 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.